A Study of Chemo +/- Low-dose Radiation as Induction Therapy in SCCHN

Model scores of the 29,894 trials active now.

Model score 48% for any early termination, 17% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2021-06-15. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancerradiationpatientscellstage
  Phrases that lowered it: effectupperlimit ofof normalcombination
• Sponsor's past termination rate: 50% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Responsible party: sponsor investigator (raises risk) · Design
• Blinding: single (lowers risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: parallel (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 95.4% (raises risk) · Drug's FDA history
• Drug's FAERS reports with a death: 22.7% (raises risk) · Drug's FDA history
• Keywords listed: 2 (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Disease area, respiratory: Yes (raises risk) · Disease area
• Sponsor's past trials: 4 (raises risk) · Sponsor's track record
• Drug's FAERS reports before start: 32202 (lowers risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study NCT01221753 · started 2011 · scored riskier than 97% of active trials terminated
• Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma NCT01794845 · started 2013 · scored riskier than 98% of active trials terminated
• Chemoradiation Treatment for Head and Neck Cancer NCT00704639 · started 2008 · scored riskier than 78% of active trials completed
• Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer NCT00721513 · started 2008 · scored riskier than 89% of active trials completed
• Radiation + Cisplatin or Panitumumab in Locally Advanced Stage III or Stage IV Head and Neck Cancer NCT00820248 · started 2008 · scored riskier than 97% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.